Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock found a bottom after sell-off (tax-losses) in the mid-December 2012 and now offers a solid trading opportunity. Besides technical analysis, there are more reasons to join this trade: CPRX announced on December 27th that it received a Nasdaq Staff Deficiency Letter for not compliance with the Minimum Bid Price requirement ($1/share) […]